Elubrixin (SB-656933) inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowel disease and airway inflammation. Elubrixin is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

Tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate inhibit of human recombinant EGLN-1 as substrate after 20 mins by mass spectrophotometric analysis.

Mercaptoethylguanidine (MEG) dihydrobromide is a selective inducible nitric oxide synthase inhibitor and peroxynitrite scavenger with potential for inflammatory bowel diseases research.

TCJL37, a potent, selective, and orally bioavailable inhibitor of TYK2, exhibits a K i value of 1.6 nM. It is useful for researching inflammatory bowel diseases (IBD) [1].

Elubrixin tosylate (SB-656933 tosylate) is a high-potency, selective, competitive, and reversible CXCR2 antagonist, as well as an antagonist of the IL-8 receptor. It effectively inhibits upregulation of neutrophil CD11b (with an IC50 of 260.7 nM) and shape change (with an IC50 of 310.5 nM). This compound holds promise for the study of inflammatory diseases, including inflammatory bowel disease and airway inflammation.

CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).

Vercirnon (Traficet-EN) is a selective and potent antagonist of CCR9 (IC50: 10 nM). It is also used in the research of inflammatory bowel diseases.

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity, physicochemical properties and pharmacokinetic profile.

LON63114, also known as FFA2-Agonist-1 is a selective orthosteric agonist of human FFA2. FFA2-Agonist-1 is potentially useful in the treatment of gastrointestinal disorders and inflammatory bowel diseases. LON63114 was reported in WO2011076732. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase that stabilizes hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible factor-2 (HIF-2). Potential for HIF-1α-related diseases (including peripheral vascular disease (PVD), heart failure, coronary artery disease (CAD), ischaemia, anaemia, colitis and other inflammatory bowel diseases).